FDA approves novel Bayer drug Sunharbo to reduce recurrent stroke risk
The Food and Drug Administration approved Bayer's new medication Sunharbo, which prevents recurrent strokes without increasing bleeding risks.
FTMQ Health, written by our newsroom0 views

The United States Food and Drug Administration approved a new medication from Bayer on Monday to reduce the recurrence of stroke. STAT News and UA.NEWS both reported that the drug, which will be marketed under the brand name Sunharbo, represents the first entry in a novel class of blood thinners designed to prevent clot formation without increasing the risk of bleeding. [1][3]
Many traditional blood thinners are not prescribed to stroke patients because of concerns over bleeding risks. According to STAT News, Sunharbo targets stroke prevention by inhibiting factor XIa, a specific protein mechanism thought to stop harmful blood clots while avoiding additional bleeding dangers. [1]
STAT News reported that in a Phase 3 clinical trial involving human participants who had previously suffered a stroke and were receiving standard stroke therapies, 8.4 percent of participants experienced positive outcomes with the new treatment approach. [1]
Bayer previously commercialized acetylsalicylic acid under the trademark Aspirin in 1899, which established a major milestone in mass-produced pain relievers. The pharmaceutical firm also manufactures other oral anticoagulant medications, including rivaroxaban, which is sold under the brand name Xarelto to treat deep vein thrombosis and pulmonary emboli. [4][5]
In short
- The FDA approved Bayer's new drug Sunharbo on Monday to prevent recurrent strokes.
- Sunharbo inhibits protein XIa to prevent dangerous blood clots without raising bleeding risks.
- In a Phase 3 trial of people taking common stroke treatments, 8.4 percent of participants achieved positive results.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]STAT+: FDA approves novel Bayer drug to reduce recurrence of strokeSTAT News, 8d ago (the report this story comes from)
- [2]FDA approves novel Bayer drug to reduce recurrence of strokeSTAT, 8d ago
- [3]FDA approves Bayer’s Sunharbo to reduce recurrent stroke risk — STAT NewsUA.NEWS, 8d ago
Background
- [4]Rivaroxaban on Wikipedia
- [5]Bayer on Grokipedia
Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- FDA approves HIV drug dolutegravir for full-term newbornsTop Stories, 26d ago
- FDA approves new Roche breast cancer drug WilserdlyTop Stories, 1d ago
- FDA proposes expanding food chemical exemption without safety reviewTop Stories, 38d ago
- Stopping GLP1 receptor agonist treatment increases stroke and heart attack riskHealth Care, 6d ago
- Japan approves pitolisant for excessive daytime sleepiness in narcolepsy and sleep apneaSleep, 44d ago
More in Top Stories
- United States updates federal health data privacy regulations for patient records4h ago
- Apple launches large study to evaluate health artificial intelligence app4h ago
- United States loses official measles elimination status following severe outbreak4h ago
- GLP1 weight loss drugs linked to nutrient shortages in exploratory study4h ago
- Large and small waist sizes linked to higher death risk4h ago
- UK government to end Palantir NHS England contract in 20291d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.